Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

This year’s business critical agenda

Days begin at approx. 9 am and end at 5:30pm.
*Please note that final timings will be released 2 months before the event

Keynote Sessions
08:30 - 09:00
CEO panel: The future of care: defining the commercial model for innovation in the Australian market
  • Confront the market access hurdle by adapting to a leaner model for commercialization: leverage new capabilities including value-added services, medical, digital and pharmacy to succeed
  • Better understand the impact of medicines on your patients, their families and community: go beyond your medicines with education, adherence and support to help your patients fulfil their lives
  • How to deliver on our promises: should we explore a new way of funding via outcomes-based results

Pfizer Melissa McGregor Managing Director, Australia Pfizer

AbbVie Kirsten O'Doherty GM, ANZ AbbVie

Novo Nordisk Michala Fischer-Hansen VP and GM, ANZ Novo Nordisk

Novartis Oncology Lauren Carey General Manager Novartis Oncology

09:00 - 09:30
Unlocking the potential of precision medicine
  • Understand what is precision medicine, how will it change healthcare in the future and benefit Australian patients
  • What can Australia learn from other countries?
  • Delve into how we can build a national infrastructure to support precision medicine and generate the real-world data
  • Understand the challenges for regulatory and reimbursement bodies in Australia

Janssen Bruce Goodwin Managing Director Janssen

09:30 - 10:00
Panel: How to engage and collaborate early with your stakeholders for market access
  • Essential update from Medicines Australia
  • The importance of engaging patients and researchers, alongside government
  • Learn how to build partners to strengthen your case for value
  • Examples of positive results and treatment for patients via compassionate access approval

Shire Brad Edwards General Manager Shire

MSD Nicole Richards Executive Director, Market Access and Policy, MSD

Rare Cancers Australia Richard Vines CEO Rare Cancers Australia

09:30 - 10:00
Is Access in Australia getting harder, or are industry and government payers at a critical turning point for a sustainable future?
  • Invest in market access: engage government as a true partner to make the case for win-win reimbursement and speed up access to therapy for patients
  • Major technical innovation is reaching a new tipping point with market and payer disruption beginning, what we all need to consider strategically – rare disease perspective
  • The demand for holistic healthcare: how to be part of enabling patients access to services beyond your medicines

Alexion David Kwasha JAPAC Region Head, Vice President and Managing Director Alexion

Reimbursement “Surviving business in AU: If you can do it here you can do it anywhere”
08:30 - 09:00
How to overcome the challenges and changes in market access within Australia
  • Essential Briefing on Market Access and Policy Changes in Australia • The requirements for success of RWD for your product development and commercialisation • Understanding the shift to outcomes: is value-based pricing for you? • Breakdown team siloes: speed up your time to market to reach the shared goal of improved patient outcomes

Janssen Duncan O'Brien Executive Director, Integrated Market Access Team Janssen

09:00 - 09:30
Tactics to speed up time to market
  • Evolving roadblocks to time to market, and what can be done to ensure timely access • Updates on policy effecting access, and how this is going to effect the commercial side of the business • Case studies on successful patient centric approaches to break down barriers to access

Bayer Pharmaceuticals Matt Slabbert Head of Market Access, Australia & New Zealand Bayer Pharmaceuticals

09:00 - 09:30
Gain approval for your medicines: fully understand Therapeutic Goods Administration decision pathways
  • How the priority approval pathway works and the latest insights whether your medicine might be determined to be a priority for Australian patients • The new provisional pathway: the key to success and early access for patients, when early data seems very promising • Will you receive the approval you hoped for: where the nuance of wording helps define usage of a new medicine

Therapeutic Goods Administration Adrian Bootes Assistant Secretary, Prescription Medicines Authorisation Branch Therapeutic Goods Administration

Customer Experience and Digital Transformation
08:30 - 09:00
Digital case study: How Pfizer are optimising the customer experience for retail pharmacists
  • Improve relationships with pharmacy as an increasingly important stakeholder, to reach your patients for better health outcomes
  • Understand how Pfizer uses an omni-channel approach to create valuable experiences for pharmacists
  • Create meaningful metrics that encourage ongoing improvement

Pfizer Mark Edwards Digital Lead Pfizer

Pfizer Elaine Saad Marketing Lead - Retail Pharmacy Pfizer

09:00 - 09:30
Case study: how Aspen launched a cost-effective app for HCP engagement
  • The story of Aspen Xpress - provide HCPs with medical information in their pocket
  • Transform your content into video, audio, text and offline so doctors can access when it suits them
  • Refine and polish for long term use and improved health outcomes

Aspen Richard Clement Group Digital Marketing Manager Aspen

09:00 - 09:30
The Digital Disruption Imperative
  • Understand the characteristics of the companies leading digital disruption - and the challenges for pharma to get close
  • New trends that are challenging pharma to shift from an asset to a solution mindset
  • Case studies of the latest digital technologies that provide new opportunities for pharma, including virtual reality, periscope, hololens and more

MSD Peter Stephenson AP Multi-Channel Marketing Lead MSD

08:30 - 09:00
Select the right partners for your digital engagement projects to provide the best solutions for your patients
  • Rationale to choose the right vendor, partner, consultant or third party to result in quick deployment, effective engagement and quality UX
  • Key factors to consider in your decision-making process from goals to delivery
  • Differences and considerations between global, regional and local project

Roche Tracey Scrivens Digital Strategy Manager Roche

09:00 - 09:30
Out of Industry with Facebook: Become a Digital Leader with Multi-channel Customer Engagement
  • Embed a digital culture and collaborative mindset across functions
  • How the development of mobile technology and chat bots will enhance your ability to create personalised connections and form stronger relationships with your customers
  • Understand what the future of health in a mobile world looks like by exploring how pharma companies are taking a more connected and personal approach to communications; creatively building communities and exploring new brand opportunities.

Facebook Dan Sinfield Head of CPG Facebook

09:00 - 09:30
Google Case Study: Smarter tactics for a nimble digital strategy
  • Invest in results not in process: how to shift from creating assets to driving traffic
  • Discover strategies to speed up content creation and co-create with your audience
  • Engage customers through behavioural profiling local examples on how you can improve your customer strategy
  • Hear how google are developing better internal commercial model to keep up with technology and consumer cycles and what pharma can take-away from this

Google Daniel Webb Industry Manager Google

Your Commercial for Success in Australia: how to launch in an uncertain market
08:30 - 09:00
Do more with less: create a lean commercial model to succeed in Australia
  • Why UCB took the approach to innovate, which resulted in an integrated commercial model
  • Examine the ecosystem before you redesign your model: what commercial capabilities do you need to thrive?
  • How a lean model can break down siloes in your teams and make adaptation to change easier

UCB Shaun Holmgreen Head, Business Services UCB

09:00 - 09:30
How big pharma aligned medical, marketing and sales with collaboration
  • How to create common end-to-end goals in both planning and delivery within a large organization
  • Ensure everyone is aligned on the challenges and opportunities in their relevant geography
  • Practical tips on how to build a framework for self-assessment and use shared metrics between your teams

GSK Andrew Weekes Medical Director GSK

09:00 - 09:30
Why you should invest in medical: become a trusted source for your patients
  • Insights from Australia’s first ever MSL survey: gain value for your business and patients
  • The current and future role of MSLs and how this compares to current perceptions
  • Best practices for ensuring top performance of MSLs: how to create a competency framework for hiring and training

APPA Matthew Britland Senior Medical Manager APPA

09:00 - 09:30
Panel: Align your increasingly complex field force around true customer centricity
  • Harmonize incentives as a key tool in aligning departments
  • Communication is key: work closely to avoid competition for access– and focus on customer value
  • Deploying digital strategies to improve engagement with medical information

Alexion Lynn Sartori Director of Medical Affairs Alexion

Amicus Therapeutics Simon McErlane Medical Director- Australia & Asia Amicus Therapeutics

Fresenius Kabi Juan Villar General Manager Australia & New Zealand Fresenius Kabi

Amgen Ciara McKenna Business Unit Director- General Medicines Amgen

Stakeholder engagement: “Pharmacy is the new stakeholder but the HCP is still king”
08:30 - 09:00
Hear the patient’s voice: fireside chat with a Patient Representative
  • Hear a different side to the story: an interactive discussion with a long-term asthma sufferer
  • Understand how you can make a real difference to the quality of life of your patients
  • The importance of programs that go beyond the pill in delivering true long-term value

Novartis Jane Adams Senior Health Economics Manager Novartis

Julia Ovens Asthma Patient

09:00 - 09:30
Case study: how Epilepsy Australia and UCB have created a true partnership to deliver value to their patients
  • The process of commencing, developing and continuing pharma-patient partnerships
  • How to build long-term trust with activities initiated together for mutual benefit and positive patient outcomes
  • Examples of initiatives including digital patient education MyEpilepsyKey, HCP solutions and online books for children
  • Hear how patients have benefited from information and resources provided for them

Epilepsy Action Australia Carol Ireland CEO Epilepsy Action Australia

09:00 - 09:30
Case study: example of how Kidney Australia collaborate with pharma to educate HCPs to result in improved patient support
  • Learn from a benchmark in primary care teaching - how to work together to develop guidelines for HCPs
  • How to form long-term associations that support patients to result in improved outcomes
  • Learn from a patient education program that helped patients with end-stage kidney disease with their difficult decision-making process

Kidney Australia Lisa Murphy Interim CEO Kidney Australia

09:00 - 09:30
Case study: Brain Health Report - an international collaboration between Pharma, neurologists and patient organisations
  • Discover new strategies to co-create education programs to engage the patient
  • Steps taken and lessons learned whilst rolling out an international project across the Australian market
  • How providing information and education to help with early diagnosis and treatment resulted in improved patient outcomes

MS Australia Deidre Mackechnie CEO MS Australia

09:00 - 09:30
Panel: How will pharma’s supply-chain be disrupted in Australia?
  • Is direct distribution the new model for pharma?
  • Is this a strategy for product or portfolio?
  • What’s the key driver for change? Margin or value to the patient?
  • How does direct distribution affect your relationships with partners?

DHL Supply Chain Saul Resnick CEO Australia New Zealand, and Life Science Healthcare APAC DHL Supply Chain

Sigma Healthcare Limited Mark Hooper CEO & Managing Director Sigma Healthcare Limited

Keynote Sessions
08:30 - 09:00
CEO panel: The future of care: defining the commercial model for innovation in the Australian market
  • Confront the market access hurdle by adapting to a leaner model for commercialization: leverage new capabilities including value-added services, medical, digital and pharmacy to succeed
  • Better understand the impact of medicines on your patients, their families and community: go beyond your medicines with education, adherence and support to help your patients fulfil their lives
  • How to deliver on our promises: should we explore a new way of funding via outcomes-based results

Pfizer Melissa McGregor Managing Director, Australia Pfizer

AbbVie Kirsten O'Doherty GM, ANZ AbbVie

Novo Nordisk Michala Fischer-Hansen VP and GM, ANZ Novo Nordisk

Novartis Oncology Lauren Carey General Manager Novartis Oncology

09:00 - 09:30
Unlocking the potential of precision medicine
  • Understand what is precision medicine, how will it change healthcare in the future and benefit Australian patients
  • What can Australia learn from other countries?
  • Delve into how we can build a national infrastructure to support precision medicine and generate the real-world data
  • Understand the challenges for regulatory and reimbursement bodies in Australia

Janssen Bruce Goodwin Managing Director Janssen

09:30 - 10:00
Panel: How to engage and collaborate early with your stakeholders for market access
  • Essential update from Medicines Australia
  • The importance of engaging patients and researchers, alongside government
  • Learn how to build partners to strengthen your case for value
  • Examples of positive results and treatment for patients via compassionate access approval

Shire Brad Edwards General Manager Shire

MSD Nicole Richards Executive Director, Market Access and Policy, MSD

Rare Cancers Australia Richard Vines CEO Rare Cancers Australia

09:30 - 10:00
Is Access in Australia getting harder, or are industry and government payers at a critical turning point for a sustainable future?
  • Invest in market access: engage government as a true partner to make the case for win-win reimbursement and speed up access to therapy for patients
  • Major technical innovation is reaching a new tipping point with market and payer disruption beginning, what we all need to consider strategically – rare disease perspective
  • The demand for holistic healthcare: how to be part of enabling patients access to services beyond your medicines

Alexion David Kwasha JAPAC Region Head, Vice President and Managing Director Alexion

Register Now

Save AU $200 with our Early Bird discount. Expires Today!

Reimbursement “Surviving business in AU: If you can do it here you can do it anywhere”
08:30 - 09:00
How to overcome the challenges and changes in market access within Australia
  • Essential Briefing on Market Access and Policy Changes in Australia • The requirements for success of RWD for your product development and commercialisation • Understanding the shift to outcomes: is value-based pricing for you? • Breakdown team siloes: speed up your time to market to reach the shared goal of improved patient outcomes

Janssen Duncan O'Brien Executive Director, Integrated Market Access Team Janssen

09:00 - 09:30
Tactics to speed up time to market
  • Evolving roadblocks to time to market, and what can be done to ensure timely access • Updates on policy effecting access, and how this is going to effect the commercial side of the business • Case studies on successful patient centric approaches to break down barriers to access

Bayer Pharmaceuticals Matt Slabbert Head of Market Access, Australia & New Zealand Bayer Pharmaceuticals

09:00 - 09:30
Gain approval for your medicines: fully understand Therapeutic Goods Administration decision pathways
  • How the priority approval pathway works and the latest insights whether your medicine might be determined to be a priority for Australian patients • The new provisional pathway: the key to success and early access for patients, when early data seems very promising • Will you receive the approval you hoped for: where the nuance of wording helps define usage of a new medicine

Therapeutic Goods Administration Adrian Bootes Assistant Secretary, Prescription Medicines Authorisation Branch Therapeutic Goods Administration

Register Now

Save AU $200 with our Early Bird discount. Expires Today!

Customer Experience and Digital Transformation
08:30 - 09:00
Digital case study: How Pfizer are optimising the customer experience for retail pharmacists
  • Improve relationships with pharmacy as an increasingly important stakeholder, to reach your patients for better health outcomes
  • Understand how Pfizer uses an omni-channel approach to create valuable experiences for pharmacists
  • Create meaningful metrics that encourage ongoing improvement

Pfizer Mark Edwards Digital Lead Pfizer

Pfizer Elaine Saad Marketing Lead - Retail Pharmacy Pfizer

09:00 - 09:30
Case study: how Aspen launched a cost-effective app for HCP engagement
  • The story of Aspen Xpress - provide HCPs with medical information in their pocket
  • Transform your content into video, audio, text and offline so doctors can access when it suits them
  • Refine and polish for long term use and improved health outcomes

Aspen Richard Clement Group Digital Marketing Manager Aspen

09:00 - 09:30
The Digital Disruption Imperative
  • Understand the characteristics of the companies leading digital disruption - and the challenges for pharma to get close
  • New trends that are challenging pharma to shift from an asset to a solution mindset
  • Case studies of the latest digital technologies that provide new opportunities for pharma, including virtual reality, periscope, hololens and more

MSD Peter Stephenson AP Multi-Channel Marketing Lead MSD

08:30 - 09:00
Select the right partners for your digital engagement projects to provide the best solutions for your patients
  • Rationale to choose the right vendor, partner, consultant or third party to result in quick deployment, effective engagement and quality UX
  • Key factors to consider in your decision-making process from goals to delivery
  • Differences and considerations between global, regional and local project

Roche Tracey Scrivens Digital Strategy Manager Roche

09:00 - 09:30
Out of Industry with Facebook: Become a Digital Leader with Multi-channel Customer Engagement
  • Embed a digital culture and collaborative mindset across functions
  • How the development of mobile technology and chat bots will enhance your ability to create personalised connections and form stronger relationships with your customers
  • Understand what the future of health in a mobile world looks like by exploring how pharma companies are taking a more connected and personal approach to communications; creatively building communities and exploring new brand opportunities.

Facebook Dan Sinfield Head of CPG Facebook

09:00 - 09:30
Google Case Study: Smarter tactics for a nimble digital strategy
  • Invest in results not in process: how to shift from creating assets to driving traffic
  • Discover strategies to speed up content creation and co-create with your audience
  • Engage customers through behavioural profiling local examples on how you can improve your customer strategy
  • Hear how google are developing better internal commercial model to keep up with technology and consumer cycles and what pharma can take-away from this

Google Daniel Webb Industry Manager Google

Register Now

Save AU $200 with our Early Bird discount. Expires Today!

Your Commercial for Success in Australia: how to launch in an uncertain market
08:30 - 09:00
Do more with less: create a lean commercial model to succeed in Australia
  • Why UCB took the approach to innovate, which resulted in an integrated commercial model
  • Examine the ecosystem before you redesign your model: what commercial capabilities do you need to thrive?
  • How a lean model can break down siloes in your teams and make adaptation to change easier

UCB Shaun Holmgreen Head, Business Services UCB

09:00 - 09:30
How big pharma aligned medical, marketing and sales with collaboration
  • How to create common end-to-end goals in both planning and delivery within a large organization
  • Ensure everyone is aligned on the challenges and opportunities in their relevant geography
  • Practical tips on how to build a framework for self-assessment and use shared metrics between your teams

GSK Andrew Weekes Medical Director GSK

09:00 - 09:30
Why you should invest in medical: become a trusted source for your patients
  • Insights from Australia’s first ever MSL survey: gain value for your business and patients
  • The current and future role of MSLs and how this compares to current perceptions
  • Best practices for ensuring top performance of MSLs: how to create a competency framework for hiring and training

APPA Matthew Britland Senior Medical Manager APPA

09:00 - 09:30
Panel: Align your increasingly complex field force around true customer centricity
  • Harmonize incentives as a key tool in aligning departments
  • Communication is key: work closely to avoid competition for access– and focus on customer value
  • Deploying digital strategies to improve engagement with medical information

Alexion Lynn Sartori Director of Medical Affairs Alexion

Amicus Therapeutics Simon McErlane Medical Director- Australia & Asia Amicus Therapeutics

Fresenius Kabi Juan Villar General Manager Australia & New Zealand Fresenius Kabi

Amgen Ciara McKenna Business Unit Director- General Medicines Amgen

Register Now

Save AU $200 with our Early Bird discount. Expires Today!

Stakeholder engagement: “Pharmacy is the new stakeholder but the HCP is still king”
08:30 - 09:00
Hear the patient’s voice: fireside chat with a Patient Representative
  • Hear a different side to the story: an interactive discussion with a long-term asthma sufferer
  • Understand how you can make a real difference to the quality of life of your patients
  • The importance of programs that go beyond the pill in delivering true long-term value

Novartis Jane Adams Senior Health Economics Manager Novartis

Julia Ovens Asthma Patient

09:00 - 09:30
Case study: how Epilepsy Australia and UCB have created a true partnership to deliver value to their patients
  • The process of commencing, developing and continuing pharma-patient partnerships
  • How to build long-term trust with activities initiated together for mutual benefit and positive patient outcomes
  • Examples of initiatives including digital patient education MyEpilepsyKey, HCP solutions and online books for children
  • Hear how patients have benefited from information and resources provided for them

Epilepsy Action Australia Carol Ireland CEO Epilepsy Action Australia

09:00 - 09:30
Case study: example of how Kidney Australia collaborate with pharma to educate HCPs to result in improved patient support
  • Learn from a benchmark in primary care teaching - how to work together to develop guidelines for HCPs
  • How to form long-term associations that support patients to result in improved outcomes
  • Learn from a patient education program that helped patients with end-stage kidney disease with their difficult decision-making process

Kidney Australia Lisa Murphy Interim CEO Kidney Australia

09:00 - 09:30
Case study: Brain Health Report - an international collaboration between Pharma, neurologists and patient organisations
  • Discover new strategies to co-create education programs to engage the patient
  • Steps taken and lessons learned whilst rolling out an international project across the Australian market
  • How providing information and education to help with early diagnosis and treatment resulted in improved patient outcomes

MS Australia Deidre Mackechnie CEO MS Australia

09:00 - 09:30
Panel: How will pharma’s supply-chain be disrupted in Australia?
  • Is direct distribution the new model for pharma?
  • Is this a strategy for product or portfolio?
  • What’s the key driver for change? Margin or value to the patient?
  • How does direct distribution affect your relationships with partners?

DHL Supply Chain Saul Resnick CEO Australia New Zealand, and Life Science Healthcare APAC DHL Supply Chain

Sigma Healthcare Limited Mark Hooper CEO & Managing Director Sigma Healthcare Limited

Don't miss out - register now

Discount ends TODAY! Save AU $200 with our Early Bird discount. Don't miss out!